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Abstract
In this paper we show that DNA polymerase lambda (pol lambda) interacts with proliferating cell
nuclear antigen (PCNA) in vivo in human cells. Moreover, by using recombinant mutated PCNA, we
could demonstrate that pol lambda interacts with both the interdomain-connecting loop and the nearby
hydrophobic pocket on the anterior of PCNA and that critical residues within a helix-hairpin-helix
domain of pol lambda, important for proper DNA primer binding, are also involved in the enzyme's
interaction with PCNA. Finally, we show that the tumor suppressor protein p21(WAF1/CIP1) can
efficiently compete in vitro with pol lambda for binding to PCNA. Given the high rate of frameshift
mutations induced by pol lambda and its ability to bypass abasic sites, accurate regulation of pol lambda
activity by PCNA and p21 concerted action might be important for preventing genetic instability.
 ©2004 FASEB 
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ABSTRACT 
In this paper we show that DNA polymerase λ (pol λ) interacts with proliferating cell nuclear 
antigen (PCNA) in vivo in human cells. Moreover, by using recombinant mutated PCNA, we 
could demonstrate that pol λ interacts with both the interdomain-connecting loop and the nearby 
hydrophobic pocket on the anterior of PCNA and that critical residues within a helix-hairpin-
helix domain of pol λ, important for proper DNA primer binding, are also involved in the 
enzyme’s interaction with PCNA. Finally, we show that the tumor suppressor protein 
p21WAF1/CIP1 can efficiently compete in vitro with pol λ for binding to PCNA. Given the high rate 
of frameshift mutations induced by pol λ and its ability to bypass abasic sites, accurate regulation 
of pol λ activity by PCNA and p21 concerted action might be important for preventing genetic 
instability. 
Key words: DNA replication • cell cycle • abasic sites • protein-protein interactions 
roliferating cell nuclear antigen (PCNA) is the processivity factor for DNA polymerases 
(pol) δ and ε (1, 2) and interacts also with several proteins involved in DNA replication, 
repair and cell cycle control (3, 4), including the family Y eukaryotic pol η, pol κ, and pol 
ι (5–8). The consensus sequence Q-x-x-(I/L/M)-x-x-F-(F/Y) was shown to mediate the 
interaction of most of these proteins with PCNA; hence, it was named PIP for PCNA Interacting 
Proteins-box (9). 
Pol λ is a novel pol β-like enzyme belonging to the eukaryotic pol family X, together with pol β, 
pol µ and terminal deoxy-nucleotidyl-transferase (TdT) (10–12). However, even if critical 
residues in the active site of both pol λ and pol β are functionally conserved (13), pol λ, contrary 
P 
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 to pol β, can synthesize DNA starting from RNA primers and possesses terminal-transferase 
activity (14) and differential metal ion preferences (15). 
We have recently shown that PCNA binds to pol λ in vitro and increases its processivity (16), 
closely resembling the interaction of PCNA with pol δ (3) but differently from the Y family pols 
η, κ, and ι, where the efficiency of nucleotide incorporation and not the processivity was 
affected by PCNA. Pol ι has been proposed to interact with PCNA through the motif S-R-G-V-
L-S-F-F (in bold are the conserved PIP-box amino acids), only slightly resembling the canonical 
PIP-box (6), although there is no experimental evidence so far supporting this suggestion. Figure 
1A shows that very similar motifs are present also in pol κ and pol λ, that is, S-M-S-V-E-R-T-F 
for pol κ and S-V-P-V-L-E-L-F for pol λ (in bold are the conserved amino acids). In pol κ, there 
is also a bona fide PIP-box at the C terminus, whereas a canonical motif is lacking in pol λ. 
Sequence alignment of human pol λ with the pol X family members pol β and TdT, revealed that 
this motif belongs to a conserved helix-hairpin-helix (HhH) domain (Fig. 1B). Crystal structures 
determination have since confirmed that the HhH-motif of pol β binds Na+ or K+ ions in vivo and 
interacts with the backbone phosphate of the DNA primer (17). The crystal structure of murine 
TdT showed that an analogous HhH-motif is responsible for primer binding. In particular, the 
Lys261 of TdT, which corresponds to Lys347 of pol λ (Fig. 1B), was shown to interact with the 
phosphate backbone of the DNA strand (18). The recently solved crystal structure of pol λ in 
complex with DNA showed that this HhH domain in pol λ adopts a similar folding to pol β (19) 
and likely plays an essential role in DNA binding. 
In this work we aimed to investigate: 1) whether this structural domain of pol λ was important 
for primer binding and/or for PCNA interaction; 2) which domain of PCNA could mediate the 
interaction with pol λ; 3) whether the tumor suppressor p21WAF1/CIP1 could affect the interaction 
between pol λ and PCNA. 
MATERIAL AND METHODS 
Chemicals 
[3H]dTTP (40 Ci/mmol) and [γ-32P]ATP (3000 Ci/mmol) were from Amersham Biosciences 
(Piscataway, NJ); unlabeled dNTPs, poly(dA), oligo(dT)12−18, were from Roche Molecular 
Biochemicals (Indianapolis, IN). Whatman (Clifton, NJ) was the supplier of the GF/C filters. All 
other reagents were of analytical grade and were purchased from Merck or Fluka. 
Enzyme and proteins 
Site-directed mutations were introduced into a human pol λ overexpression plasmid (pRSETb-
hpol λ) by a PCR-based method. Recombinant human wild-type pol λ, the E330A, V334A, and 
F338A pol λ mutants were expressed and purified as described (13, 16). After purification, the 
protein was >90% homogenous, as judged by SDS-PAGE and Coomassie staining (data not 
shown). The SHV43, QLGI125, and LAPK251 mutants of human PCNA were generated, 
expressed in Escherichia coli, and purified as described previously (20). Recombinant human 
p21 was expressed and purified as described (21). 
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 Nucleic acid substrates 
The d66mer, d60mer, d73mer, and the corresponding primers were chemically synthesized and 
purified on denaturing polyacrylamide gel. For sequence details, see (13, 16). 
Enzymatic assays 
DNA polymerase assay 
Pol λ activity on poly(dA)/oligo(dT)10:1 was assayed as described by Maga and colleagues (16). 
For denaturing gel analysis, the reaction mixture included 50 mM Tris-HCl (pH 7.0), 0.25 mg/ml 
BSA, 1 mM DTT, and 1 mM MnCl2. Concentrations of enzymes, unlabeled dNTPs and 5′ 32P-
labeled primer/ template were as indicated in the figure legends. For the processivity assay, the 
enzyme was preincubated with the labeled substrate 5 min at 37°C, and then the reactions were 
performed in the absence or in the presence of 50-fold molar excess over the labeled template, of 
poly(dA)/oligo(dT) as a trap. 
Terminal transferase assay 
Pol λ terminal transferase activity on a ss 66-mer oligonucleotide was assayed as described by 
Shevelev and colleagues (13). 
Steady-state kinetic data analysis 
For kinetic analysis, enzymatic activity was measured in the presence of 25 nM pol λ wt and 
E330A and 75 nM pol λ V334A and F338A and increasing concentrations of either 
poly(dA)/oligo(dT) (10 nM, 20 nM, 50 nM, 100 nM, 200 nM, and 500 nM, as 3′-OH ends) or 
dTTP (0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM). From the variation of the reaction velocities as a 
function of the substrate concentrations, the kinetic parameters Km, kcat and kcat/Km were 
calculated according to the Michelis-Menten equation. DNA substrate titrations were carried out 
for each enzyme also in the absence or in the presence of increasing amounts of PCNA (10 nM, 
100 nM, 500 nM, as trimer). The kcat/Km values were then calculated for each enzyme in the 
presence of each PCNA concentration and in its absence. For terminal-transferase activity kinetic 
measurements, the concentrations of the 66-mer oligonucleotide used were 20 nM, 50 nM, 100 
nM, 400 nM, 2 µM, and 4 µM. Initial velocities of the reactions were measured at a 15 min time 
point, which corresponded to the midpoint of the linearity range of the reaction, as determined by 
time-course experiments. Under these conditions, the amount of substrate used was less than 
20%. 
Cell culture 
HeLa cells were grown under standard conditions and were lysed for 15 min in a high salt buffer 
(Hepes pH 7.9 100 mM, NaCl 400 mM, DTT 1 mM, PMSF 2 mM, glycerol 20%, NP-40 0.5%, β 
glycerophosphate 10 mM, Na3VO4 1 mM, 2 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 µg/ml 
bestatin). Samples were then centrifuged 10 min at 10,000 × g at 4°C, and the supernatant was 
kept as total extract. 
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 In vitro pull-down and coimmunoprecipitation assays 
For pull-down assays, either NiNTA-agarose or GTH-sepharose beads were used, whereas for 
co-IP experiments, Protein G-sepharose beads were employed, as indicated in the figure legends. 
The experiments were performed according to standard protocols. 
In vivo immunoprecipitation experiments  
PCNA immunoprecipitation 
1.5 mg of extract was diluted in buffer A (Tris-HCl pH 7.5 10 mM, MgCl2 2.5 mM, NP-40 0.5%, 
PMSF 1 mM, 2 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml bestatin, Na3VO4 0.2 mM) to have a 
final concentration of NaCl of 80 mM and were then incubated with 3 µg of antibody against 
PCNA (PC10, Santa Cruz biotechnology) or 3 µg of mouse IgG (SIGMA) as negative control for 
3 h at 4°C. Then 6 mg of protein A-sepharose (Amersham Biosciences) were added for 1 h at 
4°C. Samples were centrifuged 30 min at 13,000 × g at 4°C. The pellets were washed 3 times 10 
min at 4°C with a washing buffer (Tris-HCl pH 8 50 mM, NaCl 50 mM, KCl 75 mM, NP-40 
0.1%, 2 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml bestatin). After immunoprecipitated proteins 
were heated 5 min at 95°C in Laemmli buffer and analyzed by SDS-PAGE and Western blot. 
Pol λ immunoprecipitation  
1 µg of affinity-purified polyclonal antibody against pol λ or rabbit IgG (Vector Laboratories) 
were incubated with 25 µl of protein G sepharose (Amersham Biosciences) overnight at 4°C in a 
buffer B (Hepes pH 7.5 40 mM, NaCl 100 mM, MgCl2 8 mM, 2 µg/ml leupeptin, 1 µg/ml 
pepstatin, 1 µg/ml bestatin). After three washings with buffer B, 1.5 mg of total extract was 
added. This extract was previously diluted with buffer C (Hepes pH 7.5 40 mM, NP-40 0.05%, 
MgCl2 8 mM, 2 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 µg/ml bestatin) to have a final 
concentration of NaCl of 100 mM. Samples were incubated 3 h at 4°C and then washed three 
times with buffer C + NaCl 100 mM. After immunoprecipitated proteins were heated 5 min at 
95°C in Laemmli buffer and analyzed by SDS-PAGE and Western blot. 
RESULTS 
Pol λ and PCNA interact in vivo in human cells 
To test whether the interaction between pol λ and PCNA could be detected in vivo, 
coimmunoprecipitation experiments were performed using HeLa cells total extracts with either 
anti-pol λ or anti-PCNA antibodies. As a negative control, extracts were immunoprecipitated 
with anonymous IgGs. Recovered immunocomplexes were analyzed by Western blot. As shown 
in Fig. 2A, both endogeneous PCNA and pol λ were immunoprecipitated by anti-PCNA 
antibodies (lane 2), but not by control IgGs (lane 3). Similarly, endogeneous PCNA and pol λ 
could be coimmunoprecipitated by anti-pol λ antibodies (lane 4), but not by control IgGs (lane 
5). These results clearly indicate that these two proteins interact in vivo. 
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 Next, we generated three mutants, E330A, V334A, and F338A, all in the HhH motif of pol λ 
(Fig. 1, see also “Introduction”) to identify the domain responsible for the interaction with 
PCNA. 
Mutants V334A and F338A are essential for efficient utilization of DNA 3′-OH ends 
The kinetic parameters (Km, kcat, and kcat/Km) for the polymerization reaction catalyzed by wt pol 
λ and the E330A, V334A, F338A mutants are reported in Table 1. For the dTTP substrate, the 
efficiency parameters kcat/Km for nucleotide incorporation were not significantly different in 
mutants and wt enzymes. However, all three mutants showed a reduction in their kcat/Km values 
for the 3′-OH primer ends utilization when compared with wt, reduction which was particularly 
noticeable for V334A and F338A mutants (17 and 24-fold, respectively). These results suggest 
that the two residues might be important for proper DNA substrate utilization. Next, we asked 
whether the same mutations were affecting the capacity of pol λ to act as a terminal-
deoxynucleotidyl transferase (TdT). The kinetic parameters for nucleotide incorporation under 
TdT conditions by pol λ wt or by the E330A, V334A, and F338A mutants were calculated 
(Table 2), and, similarly to what was observed for the pol activity the three mutants showed a 3- 
to 20-fold reduced kcat/Km values for the DNA substrate with respect to the wt, with the F338A 
mutant being the most affected. The largest differences were observed in the Km values, whereas 
the apparent reaction rates (kcat) for the V334A and the F338A mutants were closer to the wt 
values. 
Taken together, the results of Tables 1 and 2 suggest that pol λ  residues V334 and F338 are 
important for proper DNA substrate utilization under both DNA polymerase and TdT conditions. 
The pol λ V334A and F338A mutants have reduced processivity and stimulation by PCNA  
Because PCNA has been shown to increase the processivity of wt pol λ (16), we decided to 
analyze its role on the reaction products catalyzed by wt pol λ and E330A, V334A, and F338A 
mutants (Fig. 2B). 
wt pol λ and E330A, V334A, and F338A mutants were tested on a heteropolymeric 17/60-mer 
oligonucleotide DNA template under processive conditions (e.g., in the presence of an excess of 
“cold” DNA as a trapping agent), either in the absence or in the presence of increasing 
concentrations of PCNA. As shown in Fig. 2B, under these experimental conditions, wt pol λ 
processivity was increased by PCNA (lanes 19–16). The E330A mutant (lanes 14–11), had a 
slightly reduced processivity which was, however, stimulated by PCNA. In agreement with the 
data in Table 1, both the V334A (lanes 9–6) and the F338A (lanes 4−1) mutants showed a 
strongly reduced processivity, which could not be stimulated by PCNA (lanes 8−6 and lanes 
3−1). 
The interaction between pol λ and PCNA is abolished by the F338A mutation 
To investigate the physical interaction of PCNA with the pol λ mutants, pull-down experiments 
were performed in which recombinant human PCNA was incubated with his-tagged wt 
recombinant human pol λ, or with the E330A, V334A, and F338A mutants, and the bound 
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 proteins were analyzed by immunoblotting with specific antibodies against pol λ and PCNA. As 
shown in Fig. 3A, significant levels of PCNA were recovered only in the presence of wt (lane 4) 
or E330A mutant pols (lane 1). A very low amount of PCNA was detected also in the presence 
of the V334A mutant (lane 2), whereas only background levels of PCNA were present when 
incubated with either the F338A mutant (lane 3) or with BSA (lane 5). Next we tested the ability 
of both wild-type and V334A and F338A pols to interact with endogeneous PCNA. A pull-down 
assay was performed by incubating recombinant his-tagged pols, either wild-type or bearing the 
V334A or F338A mutations, coupled to NiNTA-agarose beads, with HeLa cells extract. As a 
negative control, beads alone were incubated with the cell extract. As shown in Fig. 3B, PCNA 
was retained on the beads only in the presence of either the wt pol λ or the V334A mutant, but 
not in the presence of the F338A mutant. 
Pol λ interacts with the anterior of PCNA 
To determine the domain of PCNA interacting with pol λ, we have used recombinant PCNA, 
carrying mutations in three different domains of the anterior, which were previously shown to be 
essential for interaction with many PCNA partners (20). In the first mutant, the wild-type 
residues S43, H44, and V45 in the hydrophobic pocket on the C-side of the trimer, were changed 
to A (mutant SHV43). This region has been implicated in the interaction with pol δ, pol ε, and 
RF-C (22). In the second mutant, the residues Q125, L126, G127, and I128 of the interdomain-
connecting loop (ID-loop), were mutated to A (mutant QLGI125). This region was shown to be 
part of the binding site for pol δ, p21/WAF/CIP1, DNA ligase 1 (4). In the third mutant, the 
universally conserved residues L251, P253, and K254 in the C-terminal region were mutated to 
A (LAPK251). This mutant has been shown to fold correctly into a monomer, but to fail to 
trimerize, forming higher-order multimers in solution (20). 
In a first experiment, all three mutants were titrated into a pol λ assay. As shown in Fig. 3C, 
upper panel, only the QLGI125 mutant was able to stimulate pol λ activity, albeit at higher 
concentrations with respect to the wt PCNA. Both the SHV43 and LAPK251 failed to stimulate 
pol λ, the latter mutant even inhibiting the reaction at high concentrations. These results 
suggested a reduced affinity of the QLGI125 mutant for pol λ, compared with wt PCNA. To 
confirm this, the effect of the wt PCNA or the QLGI125 mutants on the relative efficiency of 
primer binding (kcat/Km) by pol λ was measured. Toward this aim, the kinetic parameters Km and 
kcat for 3′-OH primer utilization were determined (see “Materials and Methods”) in the absence 
or in the presence of different PCNA concentrations. The observed increase in these values was 
then plotted as a function of PCNA. As shown in Fig. 3C, lower panel, the QLGI125 mutant was 
able to increase the primer binding efficiency of pol λ to nearly the same extent than wt PCNA, 
but needed to be added at ~10- fold higher concentrations. Physical interaction between pol λ 
and the QLGI125 mutant was further confirmed by far-Western blot analysis (data not shown). 
Next, the ability of the SHV43 and LAPK251 mutants to interact with pol λ was tested by 
coimmunoprecipitation assays (Fig. 3D). Recombinant wt human pol λ was incubated in the 
presence of human PCNA, either the wild-type PCNA or the SHV43 and LAPK251 mutants. 
Then, polyclonal antibodies against pol λ were added to the reaction, and the immunocomplexes 
recovered. As shown in Fig. 3D, only wild-type PCNA and the LAPK251 mutant, but not the 
SHV43 mutant, could be coimmunoprecipitated together with pol λ. These results suggest that 
pol λ was making essential contacts with residues 43–45 of the hydrophobic pocket located on 
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 the anterior of PCNA, mutated in SHV43, while residues 125–128 of the ID-loop, mutated in 
QLG125. This may contribute additional stabilizing interactions to the PCNA-pol λ complex. 
Pol λ competes with p21/WAF1/CIP1 for PCNA binding 
The cell-cycle regulatory protein and Cdk inhibitor p21/WAF1/CIP1 has been shown to bind to 
PCNA and to sequester the PCNA site normally engaged in binding to the replicative pol δ (21, 
23–26). Because the pol λ binding domain on the PCNA trimer identified in this paper, overlaps 
with the one of p21, one should expect a similar competitive effect of p21 for the PCNA-pol λ 
interaction. To directly test this hypothesis, pull-down experiments were performed with GST-
tagged recombinant p21. As shown in Fig. 4A, lane 1, PCNA alone could be efficiently recruited 
by GST-p21. When incubated in the presence of equimolar amounts of pol λ, PCNA was still 
present in the pulled-down fraction together with GST-p21, but to a significantly lesser extent 
(Fig. 4A, compare lane 1 with lane 3), suggesting a direct competition between p21 and pol λ for 
binding to PCNA. Accordingly, pol λ was never detected in the pulled-down fractions, neither 
alone (lane 2), nor in combination with PCNA (lane 3). 
In a separate experiment, similar pull-downs were performed, but in the presence of different 
molar ratios of pol λ to PCNA. As shown in Fig. 4A (lanes 5 and 6), increasing the amount of pol 
λ caused a proportional reduction of the amounts of recovered p21/PCNA complexes. Pull-down 
experiments were also performed by incubating his-tagged pol λ bound to NiNTA-agarose beads 
in the presence of wt PCNA, either alone, or in combination with increasing amounts of 
recombinant p21. As shown in Fig. 4B, in the absence of pol λ, only background levels of PCNA 
were detected bound to the beads (lane 1), whereas PCNA could be pulled down efficiently when 
pol λ was present (lane 2). The addition of increasing amounts of p21 resulted in a reduction of 
the pol λ-bound PCNA recovered on the beads (lanes 3 and 4). These results suggested that p21 
efficiently competed with pol λ for binding to PCNA. Since PCNA stimulated DNA synthesis by 
pol λ, p21 should also exert a negative effect on the PCNA-dependent pol λ replication. To 
verify this, wt PCNA was titrated in a pol λ assay, in the absence or in the presence of p21. As 
shown in Fig. 4C, PCNA alone stimulated DNA synthesis by pol λ (compare lane 2 with lanes 3 
and 4). However, when a fixed concentration of PCNA was challenged with a 3- to sixfold 
excess of p21, the stimulatory effect was abolished (compare lanes 5 and 6 with lane 4). When 
similar experiments were repeated with different concentrations of PCNA and p21, a marked 
inhibition of PCNA-dependent pol λ stimulation by p21 was consistently observed (Fig. 4D). 
According to the pull-down data, showing no direct interaction between p21 and pol λ (Fig. 4A), 
no inhibition of pol λ activity was observed in the presence of increasing concentrations of p21 
alone (data not shown). Taken together, these results show that p21 can efficiently compete with 
pol λ for binding to PCNA and confirm that PCNA interacts with pol λ through the same 
residues involved in p21 binding. 
DISCUSSION 
In this paper, we showed that endogenous pol λ and PCNA can be coimmunoprecipitated from 
human cells (Fig. 2), providing the first evidence that these two proteins interact in vivo. 
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 Crystallographic studies revealed that three identical PCNA monomers form a ring-shaped 
homotrimer which encircles the double helix, but it is still able to freely slide along the DNA 
lattice. Thus, PCNA increases the processivity of a pol by preventing its dissociation while 
advancing along the template DNA (27). Our previous results showed that PCNA increased the 
processivity of pol λ by stabilizing its binding to the 3′-OH primer (16). In this paper, we have 
shown that an HhH motif of pol λ, also present in pol β, is important both for DNA interaction 
and for PCNA interaction. Single amino acidic substitutions in one of the α-helices, significantly 
reduced the DNA substrate utilization efficiency of pol λ (Tables 1 and 2). In particular, one 
mutation, F338A, at the same time reduced more than 20-fold the DNA binding efficiency of pol 
λ and completely abrogated its interaction with PCNA (Tables 1 and 2, Fig. 3). In addition, we 
have shown that the PCNA LAPK251 mutant, which does not form trimers but multimers (20), 
can bind to pol λ but does not stimulate it (Fig. 3C, D). These findings might suggest that a 
correct trimeric folding and/or stoichiometry of interaction of PCNA are necessary to bind to pol 
λ and to stabilize a particular conformation of the HhH-motif, which is optimal for DNA primer 
binding. 
The major sites of interaction between PCNA and many of its partners are the interdomain 
connecting loop (ID-loop) of PCNA (aa 121 to 132) and the facing hydrophobic pocket (aa 42 to 
46) (3, 22). By exploiting recombinant PCNA proteins carrying mutations in each of these 
domains, we have shown that residues 43−45 of the hydrophobic pocket are essential for 
interaction with pol λ (Fig. 3C, D). In addition, residues 125−128 of the ID-loop, also play an 
important role in stabilizing this interaction (Fig. 3C). 
The discovery that pol λ binds to PCNA at the same site as many other partners, can have 
implications for the regulation of such interaction. On the basis of our previous observations 
(16), we have suggested that PCNA could promote bypass of abasic sites during DNA 
replication. Abasic sites are frequent and are estimated to occur 10,000 times per cell, per day 
(28). A mechanism for the bypass of these DNA lesions in eukaryotic cells has been previously 
proposed, involving pol δ and pol ζ (29). Our data, showing that pol λ interacts with PCNA at 
the same site as pol δ, suggest the possibility of a “switching” between the replicative pol δ and 
the translesion pol λ through direct competition for PCNA, yielding to elongation of the nascent 
DNA strand past abasic sites. 
The p21/WAF1/CIP1protein is induced upon DNA damage, senescence or differentiation of cells, 
and blocks progression of the cell cycle through its interaction CDKs and PCNA (30, 31). 
Indeed, p21 can form a complex with PCNA, preventing interaction with replication factor C and 
pol δ (26). In this paper, we presented evidences that p21 can efficiently compete with pol λ for 
binding to PCNA (Fig. 4). This is the first time that p21 has been shown to prevent the 
interaction of PCNA with a pol other than pol δ and pol ε. Further in vivo studies are needed to 
investigate the physiological significance of this interaction; however, these findings raise the 
possibility that, in principle, the interaction of pol λ with PCNA might be subjected to cell cycle 
and/or checkpoint control. In particular, recent genetic data suggested that pol λ is particularly 
subjected to –1 frameshift errors (32). Thus, accurate regulation of its lesion bypass activity by 
PCNA and p21 concerted action might be important for preventing genetic instability. 
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Table 1 
 
Kinetic parameters for the DNA polymerization reaction catalyzed by wt pol λ and the E330A, V334A, 
and F338A pol λ mutants 
dTTPa 3′-OHa  
Km 
µM 
kcat 
min−1 
kcat/Km 
min−1µM−1 
Km 
µM 
kcat 
min−1 
kcat/Km 
min−1µM−1 
Wild type 14.3 (±0.5) 11 
(±1) 
0.75 
(±0.1) 
0.27 
(±0.03) 
8.7 
(±0.5) 
30.6 
(±2) 
E330A 6.1 
(±0.5) 
3 
(±0.2) 
0.5 
(±0.02) 
0.28 
(±0.03) 
5 
(±0.1) 
17 
(±1) 
V334A 1.5 
(±0.05) 
0.7 
(±0.1) 
0.46 
(±0.03) 
0.23 
(±0.02) 
0.4 
(±0.05) 
1.74 
(±0.2) 
F338A 2.4 
(±0.2) 
1.2 
(±0.2) 
0.5 
(±0.03) 
0.2 
(±0.03) 
0.25 
(±0.01) 
1.25 
(±0.2) 
aVariable substrate. Experiments have been carried out as described in Materials and Methods. The values have been calculated from three 
independent experiments. Numbers in parenthesis represent ±SD All the kinetic constants and the SD values have been calculated from nonlinear 
regression analysis of the data with the software GraphPad Prism. 
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Table 2 
 
Kinetic parameters for the terminal-deoxynucleotidiyl transferase reaction catalyzed by wt pol λ and the 
E330A, V334A, and F338A pol λ mutants 
3′-OHa  
Km 
µM 
kcat 
min−1 
kcat/Km 
min−1µM−1 
Wild type 0.43 
(±0.05) 
0.018 
(±0.5) 
0.04 
(±0.005) 
E330A 1.38 
(±0.08) 
0.037 
(±0.1) 
0.026 
(±0.001) 
V334A 0.96 
(±0.1) 
0.012 
(±0.05) 
0.012 
(±0.002) 
F338A 3.3 
(±0.3) 
0.008 
(±0.01) 
0.002 
(±0.0004) 
aVariable substrate. Experiments have been carried out as described in Materials and Methods. The values have been calculated from three 
independent experiments. Numbers in parenthesis represent ±SD. All the kinetic constants and the SD values have been calculated from nonlinear 
regression analysis of the data with the software GraphPad Prism. 
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Fig. 1 
 
 
 
Figure 1. The putative PCNA binding domain of pol λ lies in a conserved HhH-motif. A) Sequence alignment of the 
putative PIP-box of human pol ι, pol κ, and pol λ. Conserved residues are boxed. B) Sequence alignment of the region 
surrounding the putative PCNA binding domain of pol λ, with the corresponding region of human pol β (betahu), murine 
Tdt (tdtmus) and human Tdt (tdthu). The putative PIP-box of pol λ is boxed. Asterisks indicate the amino acids mutated for 
the purpose of this study. The corresponding secondary structure elements are indicated on the bottom: H, helix; h, hairpin. 
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Fig. 2 
 
                       
 
 
Page 15 of 20
(page number not for citation purposes)
Figure 2. Physical interaction of pol λ and PCNA in vivo and biochemical properties of the pol λ V334A and 
F338A mutants. A) Pol λ and PCNA interact in vivo in human cells. Coimmunoprecipitation experiments of 
endogeneous pol λ and PCNA were performed as described in Materials and Methods, by using total extracts of HeLa 
cells. Immunoprecipitated proteins were detected by immunoblot analysis with either anti-pol λ (upper panel) or anti-
PCNA (lower panel) antibodies. Lane 1, 1/10th of the total input was loaded as positive control for the antibodies 
detection; lane 2, immunoprecipitation with anti-PCNA mouse monoclonal antibodies (PC-10); lane 3, 
immunoprecipitation with mouse IgG (SIGMA) as negative control; lane 4, immunoprecipitation with anti-pol λ rabbit 
polyclonal antibodies; lane 5, immunoprecipitation with rabbit IgG (Vector Laboratories) as negative control. B) The 
V334A and F338A mutants of pol λ show reduced processivity. The wt pol λ (lanes 16–20), and the E330A (lanes 11–
15), the V334A (lanes 6–10) and the F338A (lanes 1–5) mutants, were assayed on the 5′-end labeled 17/60-mer substrate 
(25 nM). Amounts of enzyme used are indicated at the top of figures. Reaction products were separated by denaturing 
PAGE. Preformed enzyme/DNA complexes were incubated in the absence (lanes 5, 10, 15, and 20) or in the presence 
(lanes 16–19 for wt pol λ; lanes 11–14 for the E330A mutant; lanes 6–9 for the V334A mutant; lanes 1–4 for the F338A 
mutant) of a 50-fold molar excess of poly(dA)/oligo(dT) as a trap and in the presence of increasing amounts of PCNA 
(lanes 16–18 for wt pol λ; lanes 11–13 for the E330A mutant; lanes 6–8 for the V334A mutant; lanes 1–3 for the F338A 
mutant). PCNA concentrations used are indicated on bottom of each lane. The positions of the 17-mer primer and of the 
60-mer full-length product are indicated on the right side of the panel. 
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Fig. 3 
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Figure 3. The F338A mutation abolishes the physical interaction of pol λ with the anterior of PCNA. A) Pull-down 
assay of recombinant PCNA and recombinant pol λ. Recombinant human PCNA (5 µg) was incubated with recombinant 
his-tagged human pol λ either wt (lane 4, 3 µg), or the E330A (lane 1, 5 µg), V334A (lane 2, 5 µg) and F338A (lane 3, 4.5 
µg) mutants. In a control reaction, PCNA was incubated in the presence of 5 µg of BSA (lane 5). Then, NiNTA−agarose 
beads were added to each reaction. Pulled-down fractions were analyzed with antibodies specific to pol λ and PCNA. The 
position of the proteins reacting with each antibody is indicated on the left side of the panel. B) Pull-down assay of 
recombinant pol λ and human endogeneous PCNA. Recombinant his-tagged human pol λ either wt (lane 1, 3 µg), or the 
V334A (lane 2, 5 µg) and F338A (lane 3, 4.5 µg) mutants bound to NiNTA-agarose beads were incubated with HeLa cells 
total extract (500 µl, 6 mg/ml). As negative control, 5 µg of BSA were incubated in the presence of the beads and the 
extract (lane 4). Samples were processed as described in Materials and Methods and analyzed with antibodies specific to 
pol λ and PCNA. The position of the proteins reacting with each antibody is indicated on the left side of the panel. C) 
(upper panel) Recombinant human PCNA, either wild type (solid circles), or the LAPK251 (squares), QLGI125 (open 
circles), and SHV43 (triangles) mutants, were titrated in the presence of 25 nM pol λ and 50 nM (3′-OH ends) of the 
homopolymeric DNA template poly(dA)/oligo(dT). Reactions were carried out as described in Materials and Methods. 
Total amounts of incorporated radioactive dTTP were plotted as a function of the PCNA concentrations (expressed as 
trimers). (lower  panel). Pol λ (25 nM) was tested under the conditions described in Materials and Methods in the 
presence of increasing concentrations of poly(dA)/oligo(dT). From the variation of the reaction velocities as a function of 
the DNA substrate concentrations, the kinetic parameters Km, kcat and kcat/Km were calculated in the absence or in the 
presence of increasing amounts of PCNA, either wt (circles) or the QLGI125 mutant (triangles). The increase in the 
kcat/Km values, calculated for each set of reactions with respect to the control without PCNA, was plotted as a function of 
the PCNA concentrations. D) Coimmunoprecipitation of pol λ and PCNA with polyclonal anti-pol λ antibodies. Human 
recombinant pol λ (500 ng) was incubated in the presence of PCNA (2 µg) wild type (lane 1), or the SHV43 (lane 2) and 
the LAPK251 (lane 3) mutants, in PBS. Anti-pol λ antibodies coupled to Protein G-Sepharose beads were then added. As 
a negative control, PCNA wild type was subjected to immunoprecipitation with anti-pol λ IgG-covered beads but in the 
absence of pol λ (lane 4). Beads were washed and the bound immunocomplexes were transferred to a membrane and 
probed with either anti-pol λ antibodies (upper panel) or with anti-PCNA antibodies (lower panel). 
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Fig. 4 
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Figure 4. The p21 protein competes with pol λ for binding to PCNA. A) Pull-down assay were performed by 
incubating GST-p21 (500 ng) with either PCNA alone (1 µg, lane 1 and lane 4), or pol λ alone (0.75 µg, lane 2), or both 
PCNA and pol λ at different PCNA/pol λ molar ratios (1/1, lane 3; 1/2 lane 5; 2/1, lane 6). Glutathione-sepharose beads 
were then added and washed, and the bound proteins were visualized by immunoblotting with antibodies against pol λ 
(upper panel), p21 (middle panel) or PCNA (lower panel). Lane 7, negative control with pol λ and PCNA incubated 
together with the beads in the absence of GST-p21. Quantification of the blots is shown at the bottom of the panel as 
relative (%) amounts of recovered PCNA with respect to the controls. B) Pull-down assay were performed by incubating 
his-tagged recombinant human pol λ (500 ng) with wt PCNA (500 ng), either alone (lane 2) or in combination with 200 
ng (lane 3) or 400 ng (lane 4) of p21. Ni-NTA-beads specific for his-tag binding, were then added and washed, and the 
bound proteins were visualized by immunoblotting with antibodies against pol λ (upper panel), or PCNA (lower panel). 
Lane 1: negative control with wt PCNA incubated together with the beads in the absence of pol λ. Quantification of the 
blots is shown at the bottom of the panel as relative (%) amounts of recovered PCNA with respect to the controls. C) Pol 
λ reactions were carried out as described in Materials and Methods, in the presence of the 5′-end labeled DNA 
oligonucleotide primer/template 18/73-mer (see Materials and Methods for sequence details), and in the absence (lane 2) 
or in the presence of increasing amounts of wt PCNA (20 nM, lane 3; 50 nM, lane 4) either alone or in combination with 
increasing amounts of p21 (150 nM, lane 5; 300 nM, lane 6). Products were resolved on a 7M Urea/20% PAA-gel. D) 
Recombinant human wt PCNA, was titrated in the presence of 20 nM pol λ and 50 nM (3′-OH ends) of the 
homopolymeric DNA template poly(dA)/oligo(dT), either in the absence (squares) or in the presence of 200 nM p21 
(triangles) or 400 nM p21 (circles). Reactions were carried out as described in Materials and Methods. Total amounts of 
incorporated radioactive dTTP in the absence or in the presence of PCNA were determined to calculate the stimulation of 
pol λ activity by PCNA. The resulting stimulation (-fold) was then plotted as a function of the PCNA concentrations 
(expressed as trimers). 
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